On Monday, Citi reaffirmed its positive stance on Revvity Inc (NYSE:RVTY) stock, maintaining a Buy rating and a price target of $135.00. Revvity reported its second quarter 2024 revenue at $692 million, which represents a slight 1% year-over-year organic decline, aligning with both the company's guidance and the consensus estimate of $690 million. The company's adjusted earnings per share (EPS) of $1.22 exceeded the consensus forecast of $1.12, attributed primarily to a stronger operating profit margin (OPM).
By segment, Revvity's Life Sciences division experienced a 6% year-over-year organic decline, while the Diagnostics segment enjoyed a 3% organic growth. The Life Sciences results were influenced by challenges in instrumentation and pharmaceutical spending, which were somewhat mitigated by robust growth in the software business. In Diagnostics, the ImmunoDx product line continued to perform well, although Applied Genomics faced a low double-digit decline.
Looking ahead, Revvity has updated its full-year 2024 guidance, projecting revenues to be between $2.77 billion and $2.79 billion, which sustains a 2% year-over-year organic growth. The company also anticipates adjusted operating profit margins to range from 28.0% to 28.5%, with adjusted EPS expected to be between $4.70 and $4.80, marking an increase of $0.10 from previous estimates.
Citi's commentary highlighted the company's positive margin performance and indicated that during the earnings call, further details regarding revenue and margin trends for the second half of the year, market activities, and the outlook for China are anticipated.
InvestingPro Insights
Revvity Inc (NYSE:RVTY) continues to draw attention with its recent financial performance and market activities. According to InvestingPro data, Revvity has a market capitalization of $14.21 billion and is trading at a high earnings multiple with a P/E ratio of 95.77. However, when adjusted for the last twelve months as of Q1 2024, the P/E ratio appears more moderate at 39.35. The company's revenue for the last twelve months stood at $2.73 billion, despite a year-over-year decline of 9.85%. Importantly, Revvity's gross profit margin remains strong at 55.5%, underscoring the company's ability to maintain profitability.
From an operational standpoint, two InvestingPro Tips highlight the company's strategic maneuvers: management's aggressive share buybacks and the maintenance of dividend payments for 54 consecutive years, which may appeal to long-term investors seeking stable returns. Additionally, Revvity's liquid assets surpass its short-term obligations, providing a buffer against market volatility and financial stress. With analysts predicting profitability for the current year and a net income expected to grow, Revvity's financial health is a focal point for investors.
For those considering an investment in Revvity, there are additional InvestingPro Tips available that delve deeper into the company's performance and potential. By using coupon code PRONEWS24, readers can get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription to access these insights. With a total of 12 additional tips listed on InvestingPro, investors can gain a comprehensive understanding of Revvity's market position and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.